+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Efficacy and tolerability of oral sumatriptan in the treatment of acute migraine



Efficacy and tolerability of oral sumatriptan in the treatment of acute migraine



East African Medical Journal 72(8): 479-482



An open prospective study of the efficacy and tolerability of oral sumatriptan in the treatment of acute migraine attacks at the Kenyatta National Hospital, Nairobi, Kenya, is presented. Thirty two patients were initially recruited and 24 completed the trial giving a drop-out rate of 25%. The age range was 17 to 55 years with a mean of 35 years. Sumatriptan was found to be effective in 22 (92%) out of 24 patients. Side effects occurred in 38% (9/24) patients. These were mild and transient and included nausea, vomiting, numbness of limbs, fever and a feeling of heat in the head. It is concluded that oral sumatriptan is an effective drug in the treatment of acute migraine headaches. It has few side effects and is well tolerated by majority of patients.

(PDF emailed within 1 workday: $29.90)

Accession: 008587512

Download citation: RISBibTeXText

PMID: 7588137


Related references

The Tolerability, Safety and Efficacy of Oral Sumatriptan 50Mg and 100Mg for the Acute Treatment of Migraine in Adolescents. Cephalalgia 15(16_suppl): 99-99, 1995

Efficacy and tolerability of oral sumatriptan in Indian patients with acute migraine : a multicentre study. Neurology India 46(2): 105-108, 1998

Efficacy and tolerability of eletriptan vs sumatriptan 100 mg for the acute treatment of migraine. European Journal of Neurology 10(Supplement 1): 71, 2003

Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: Defining the optimum doses of oral sumatriptan. Headache 38(3): 184-190, 1998

Efficacy and safety of sumatriptan tablets in the acute treatment of migraine Defining the optimum doses of oral sumatriptan. Journal of the Neurological Sciences 150(SUPPL ): S41, 1997

Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders. Cephalalgia 31(7): 786-796, 2011

Efficacy and tolerability of eletriptan through the clinical dose range vs sumatriptan 100 mg for the acute treatment of migraine. Cephalalgia 23(7): 701-702, 2003

Comparison of the efficacy and tolerability of eletriptan through the clinical dose range vs sumatriptan 100 mg for the treatment of acute migraine. Neurology 60(5 Supplement 1): A169-A170, March 11, 2003

A double-blind placebo-controlled study assessing the efficacy and tolerability of 50 mg sumatriptan tablets in the acute treatment of migraine. Sumatriptan Tablets S2CM07 Study Group. International Journal of Clinical Practice. Supplement 105: 7-15, 2000

Clinical measures of efficacy, safety and tolerability for the acute treatment of migraine A comparison of eletriptan , sumatriptan and placebo. Neurology 50(4 SUPPL 4): A376, 1998

A comparison of the cost-effectiveness of almotriptan and sumatriptan in the treatment of acute migraine using a composite efficacy/tolerability end point. Journal of Managed Care Pharmacy 10(3): 259-265, 2004

Open-labeled long-term study of the efficacy, safety, and tolerability of subcutaneous sumatriptan in acute migraine treatment. Cephalalgia 19(7): 676-683, Sept, 1999

Comparison of the efficacy and tolerability of eletriptan 40 mg and sumatriptan 100 mg for the acute treatment of migraine Results of a multicenter, randomized, placebo-controlled trial. Neurology 60(5 Supplement 1): A494-A495, March 11, 2003

Total Migraine freedom for breath powered intranasal delivery of 22 mg Sumatriptan Powder (Avp-825) Versus 100 mg oral sumatriptan from the compass study of acute treatment of Migraine. Value in Health 18(3): A278-A279, 2015

A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults. Clinical Therapeutics 28(4): 517-526, 2006